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Abstract: This paper described an improved method for high-throughput and sensitive determination
of zearalenone and its five metabolites (zearalanone, α-zearalenol, β-zearalenol, α-zearalanol and
β-zearalanol) in human serum. Serum samples were measured both before and after enzyme
hydrolysis to assess the free and total amount of each compound by ultra-performance liquid
chromatography–tandem mass spectrometry (UPLC-MS/MS) in multi reaction monitoring (MRM)
mode following off-line 96-well µElution solid-phase extraction (SPE). All the analytes were
completely separated on a C18 column within 6 min. It enabled multi-sample preparation at the
same time eliminating tedious evaporation and reconstitution steps, allowing 96 (one plate) samples
to be processed and analyzed within 24 h. Using an isotope labelled internal standard (13C-ZEN),
high recoveries were achieved for all the compounds in the range 91.6%–119.5%, with intra-day and
inter-day relative standard deviations (RSDs) of less than 8%. The limits of detection (LOD) and the
limits of quantification (LOQ) were 0.02–0.06 ng mL−1 (0.6–2 fmol) and 0.1–0.2 ng mL−1 (3–6 fmol),
respectively, demonstrating a notable enhancement in sensitivity compared to the existing methods.
The validated method was applied to the analysis of paired urine and serum samples collected from
125 healthy individuals in Henan Province, locating in the middle area of China. ZEN metabolites in
human serum were significantly lower than those in urine. Only one serum sample was positive for
ZEN after enzyme digestion, whereas at least one of ZEN biomarkers was detected in 75.2% of the
paired urine samples. Some comparison and discussion were also included in this paper.
Keywords: zearalenone; metabolites; serum; 96-well µElution SPE; UPLC-MS/MS
1. Introduction
Zearalenone (ZEN) is a naturally occurring mycotoxin produced by several species of Fusarium
molds [1,2]. Many crops can be easily infested by these molds and thereby contaminated by ZEN.
Hence, humans and animals could be at high risk of being exposed to ZEN through the intake of
contaminated food or feed. ZEN showed adverse effects on reproductive systems of mammalian
species [2–5], despite its relatively low acute toxicity. According to some reports regarding blood
parameters, ZEN was also evidenced to be haematotoxic and hepatotoxic [3,6,7].
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After ingestion, ZEN is primarily metabolized to two hydroxyl isomers α-zearalenol (α-ZOL)
and β-zearalenol (β-ZOL) [1,8,9], which can be subsequently reduced to α-zearalanol (α-ZAL) and
β-zearalanol (β-ZAL), respectively [10,11]. A small portion of the α-ZAL is also found to be converted
to β-ZAL and zearalanone (ZAN) [12]. Besides, these metabolites as well as ZEN itself can be partially
conjugated with glucuronic acid and substantially excreted in bile. The glucuronide of ZEN may also
be re-absorbed and metabolized further by intestinal mucosal cells, ultimately entering the liver and
the systemic circulation via the portal blood supply [13].
Humans are easily exposed to ZEN through the food consumption [14]. For the past decades,
exposure assessment of mycotoxins was conventionally performed by combining the occurrence
data with the food consumption data [15–18]. However, due to the heterogeneous distribution of
mycotoxins in food and variability of individual toxicokinetics, this approach is considered to be
not quite reliable. Hence, an internal exposure strategy directly detecting mycotoxin biomarkers in
biological fluids could be more accurate and reliable for assessment purpose [3]. It seems important to
develop a method to satisfy the current need.
A number of approaches to quantify ZEN and its metabolites have been proposed for biological
samples in last decade, which are commonly performed with gas or liquid chromatography coupled
to mass or tandem mass spectrometry [19–27]. Among these methods, liquid chromatography-tandem
mass spectrometry (LC-MS/MS) gradually became a prior technique for mycotoxin analysis in
biological samples for its high selectivity and sensitivity. However, since the scarcity of human
serum or plasma samples, some of the methods was applied to analyze animal serum or plasma [28,29].
And some of the applications limited their detection to ZEN and one (ZAN) [30] or two (α-ZOL,
β-ZOL) [31] metabolites. Furthermore, ZEN and its metabolites were easy to form conjugates, such as
ZEN-14-glucuronic acid (ZEN-14-GlcA), ZEN-74-GlcA and α/β–ZOL-14-GlcA in vivo. Some works
published previously [20,27] failed to monitor the conjugated forms. A strategy involving enzymatic
hydrolysis was then developed and applied to chicken and pig serum [24]. However, the defects
of labor-intensive and time-consuming operation (liquid–liquid extractions, solid phase extraction,
evaporation and reconstitution) restricted its further application in large-scale sample analysis.
Recently, a method has been successfully established to determine the total (free + conjugated)
amount of ZEN and its metabolites in human serum, involving enzymatic digestion, sample cleanup
and UPLC-MS/MS analysis [32]. This method achieved higher sensitivity but still had drawback
of time-consuming due to the step of evaporation and reconstitution. To address such an issue,
a material (96-well µElution plate) for high-throughput sample preparation was employed in this
work, allowing for the simultaneous preparation of multiple samples, avoiding evaporation step and
meanwhile reducing the time and labor consumed.
The aim of this work was to develop a high-throughput and sensitive method for the quantitation
of ZEN and its biomarkers (both total and free) in serum, using UPLC-MS/MS technique combined
with 96-well µElution plate. The method provided the capability of simultaneous multi-sample
processing and chromatographic baseline separation of all target analytes, highly improving the
efficiency of human biomonitoring. The proposed method was applied to the analysis of 125 human
serum samples from healthy volunteers whose paired urine samples are also available.
2. Materials and Methods
2.1. Chemicals and Reagents
The certificated standard solutions of ZEN, ZAN, α-ZAL, β-ZAL, α-ZOL, β-ZOL and isotope
labeled internal standard (IS) 13C18-ZEN (25 µg mL−1) were from Romer Labs (Tulln, Austria).
Beta-glucuronidase (produced from E.coli) used for enzyme digestion was purchased from
Sigma-Aldrich (MO, USA). Acetonitrile and methanol were of LC-MS grade. Formic acid,
acetic acid and ammonia acetate (HPLC grade) were supplied by Fisher Scientific (Leicestershire,
United Kingdom). Potassium phosphate dibasic and potassium phosphate monobasic (analytical
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grade) were supplied by Sinopharm (Beijing, China). A Milli-Q system (Millipore Corp., Bedford,
MA) provided deionized water (18.2 MΩ cm) for all study. A mixed standard solution was prepared
with concentration of 1 µg mL−1 for each analyte and stored at 4 ◦C. The working solutions of
mixed standard were prepared in initial mobile phase at the beginning of each batch of measurement.
The enzyme solution was freshly prepared by dissolving 14.4 mg β-glucuronidase (694300 U g solid−1)
in 10 mL of 0.075 mol L−1 phosphate buffer (pH 6.8, prepared with potassium phosphate monobasic
and potassium phosphate dibasic) according to the instruction of supplier on the day of use.
The Oasis®PRiME HLB 96-well µElution plate (3 mg sorbent per well) were purchased from Waters
(Milford, MA, USA).
2.2. Sample Collection and Storage
Serum samples were collected from 125 healthy volunteers in Henan province, China. A written
and approved informed consent was given from all the participants; and the proposal was approved by
the ethics committee of CFSA. Samples were numbered and stored at −70 ◦C until analysis. Since the
lack of commercial blank serum matrix, samples with undetected levels of the analytes were selected
as blank matrices in method evaluation and quality control (QC).
2.3. Standard Solution and QC Samples
The calibration standard solutions at levels of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20 and 50 ng mL−1 for
each analyte were made by serial dilutions of the mixed standard solution. Each calibration standard
solution contained 25 µg mL−1 of 13C18-ZEN as internal standard. QC samples were prepared at
low, medium and high concentrations (0.5, 1 and 5 ng mL−1) by spiking blank serum matrix with
standard mixture.
2.4. Sample Preparation
For the free analyte.
After thawed at room temperature, serum samples were centrifuged at 8000×g for 20 min at
4 ◦C. 13C18-ZEN was added to 100 µL supernatant as internal standards with final concentration
of 25 µg mL-1, followed by a dilution with 100 µL of phosphate buffer (pH 6.8, 0.075 mol L−1).
Under appropriate vacuum conditions, Oasis®PRiME HLB µElution plate was pretreated by methanol
and water (500 µL of each) for conditioning and then loaded with the diluted samples which was
allowed to slowly flow through the cartridge at a rate about 0.5 mL min−1. Subsequently, the wells were
washed with 500 µL of water and then 500 µL of methanol/water (1/1, v/v) to remove interferences.
Finally, the analytes absorbed to the cartridge were eluted twice with 50 µL of methanol each and
collected. After a 1:1 dilution with water, the solution was injected for UPLC-MS/MS analysis.
For the total (free + conjugate) analyte.
After being thawed, centrifuged and spiked with internal standards, 500 µL of the serum sample
was mixed with 500 µL enzyme solution containing 500 units of β-glucuronidase and shaken in
a water-bath at 37 ◦C over night. Then the resulted solution was centrifuged (8000×g; 20 min; 4 ◦C);
and 200 µL of the supernatant was loaded onto the preconditioned (as mentioned above) PRiME HLB
µElution plate. The following steps were exactly the same as described above.
2.5. LC-MS/MS Analysis
An ACQUITY UPLC™ I-Class system (Waters, MA, USA) combined with Xevo®TQ-S tandem
quadrupole mass spectrometer (Waters, MA, USA) was used for the analysis. Instrument control and
data collecting and processing were carried out using Masslynx software (version 4.1).
The target compounds were separated on a UPLC column (CORTECS™ C18 Column,
2.1 × 100 mm, 1.6 µm) in combination with a guard column of the same type under a gradient
program. Water (solvet A) and acetonitrile/methanol (20/80, v/v, solvent B) were used as mobile
phase, with a flow rate of 0.4 mL/min. A gradient elution started with 50% B and then was performed
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as following: 0–4 min (linear gradient to 66% B), 4–4.1 min (immediately increased to 90%), 4.1–6.0 min
(90% B), 6.0–6.1 min (returned to 50% B), 6.1–8.0 min (50% B). The column was maintained at a constant
temperature of 40 ◦C and the injection volume was 10 µL.
The detection was performed on a Xevo® TQ-S tandem quadrupole mass spectrometer equipped
with ESI source. The instrument parameters were optimized by infusing standard solution of each
analyte in multiple reaction monitoring (MRM) mode. Ion spray voltage was set to−2.8 kV in negative
mode. Optimum cone voltages (CV) and collision energies (CE) for a scheduled MRM transition were
shown in Table 1. The source temperature was set to 150 ◦C. Nitrogen was used as the cone gas and
desolvation gas at settings of 150 L h−1 and 900 L h−1, respectively. Argon was used as the collision
gas (0.15 mL/min).
Table 1. MS/MS transitions of ZEN and its metabolites.
Analyte Precursor Quantificationion CV/CE
1 Confirmation
ion CV/CE
1 RT2
ZEN 317.1 175.0 20/24 130.9 20/32 3.24
α-ZOL 319.1 159.8 6/30 174.1 6/20 2.78
β-ZOL 319.1 159.8 36/28 174.1 36/26 2.11
α-ZAL 321.1 277.0 6/20 303.1 6/22 2.60
β-ZAL 321.1 303.1 26/20 277.3 26/28 1.92
ZAN 319.1 275.0 48/22 205.1 48/22 3.10
13C-ZEN 335.2 139.9 20/32 185.0 20/24 3.24
1 CV, cone voltage (V); CE, collision energy (eV). 2 RT, retention time (min).
2.6. Method Validation
The linearity, selectivity, accuracy, precision, sensitivity and carry over were evaluated refer to
the guideline for bioanalytical assay validation defined by the US Food and Drugs Administration
(FDA) [13]. The method recovery (RM) which served as accuracy was evaluated at three spiking
levels (0.5 ng/mL, 1.0 ng/mL and 5.0 ng/mL) in blank serum with internal standard correction of
13C18-ZEN. To determine the apparent recovery (RA), extraction recovery (RE) and matrix effects
(signal suppression/enhancement, SSE), three types of calibration curves were established as follows:
standard calibration curve prepared in neat solvent as Set I, matrix-matched standard curve using
blank serum matrices fortified before and after sample preparation as Set II and Set III, respectively.
The RA, RE and SSE were determined by dividing the slope of Set II by the slope of Set I, the slope of
Set II by the slope of Set III and the slope of Set III by the slope of Set I, respectively.
3. Results and Discussion
3.1. Optimization of Mass Conditions
The MS/MS condition was optimized on a Xevo® TQ-S by individual infusion of each compound.
To obtain the most intensive response of precursor ions, ionization mode, cone gas flow, desolvation gas
flow and temperature, source temperature, capillary voltage and cone voltage were manually
optimized in steps. Negative mode with capillary voltage set at −2.8 kV was adopted for all the
analytes; other parameters were recommended in the method section. After that, the collision energy
(CE) for each compound was tuned up individually to generate the most intensive and stable product
ions. Two product ions were selected and optimized for each compound in MRM mode, one for
quantification and another for identification, as listed in Table 1.
3.2. Chromatographic Separation
The main factors that affect chromatographic behavior were investigated aiming for a sufficient
chromatographic separation, including UPLC columns, mobile phase, additives and gradient program.
Waters CORTECS™ C18 UPLC column provided the optimal resolution and stability for all compounds
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and was chosen for further studies. Several combinations of mobile phase were separately evaluated,
that is, the additives (formic acid, acetic acid, ammonium formate or ammonium acetate) in water,
the organic modifier (methanol or acetonitrile) and the gradient elution program. Common additives
like formic acid, ammonium formate, acetic acid and ammonium acetate gave slight influence
on intensity and no contribution for separation. However, the organic modifier considerably
helped the separation. ZEN, ZAN and α-ZOL were hardly separated completely while using
methanol or acetonitrile alone as the organic modifier, which was also discussed previously [33].
Eventually, a mixture of acetonitrile and methanol (20/80, v/v) was employed and provided a complete
baseline separation of all compounds within an 8-min run time. A chromatogram of standards mixture
of all analytes was presented in Figure 1.
Figure 1. The overlaid chromatography of standard solution (10 ng mL-1 of each analyte).
3.3. Sample Preparation
As an accepted extraction method, solid-phase extraction (SPE) was widely used in the field of
ZEN analysis. However, high labor-intensity and time-consuming limited the further application in
large-scale analysis. To address such issues, a high-throughput sample preparation method using
a 96-well µElution plate was introduced to extract ZEN and its derivatives from human serum samples.
The main parameters that affect extraction procedure were optimized including loading, washing and
elution conditions.
Phospholipids, carbohydrates, mineral salts and other metabolites in the serum may cause the
endogenous interferences or the risk of cartridge clogging. Hence, all samples were 2-fold diluted with
phosphate buffer or β-glucuronidase solvent before loading onto the plate.
The washing and elution buffer directly affected the matrix effect and recovery. Spiked serum
samples (both before and after enzymatic digestion) with the concentration of 10 ng mL−1 for each
analyte were used in the test of selection. To remove the salts and other polar interferences in serum,
the plate was washed with 500 µL of water after loading as a weak wash step. For further cleanup,
a selection of strong wash solvent was performed by washing the cartridge with methanol/water
buffer (ranged from 5% to 100% methanol, v/v) and the effluent were collected for analysis of target
compounds. All the analytes started to flow out at 50% methanol and were completely eluted by
pure methanol. Hence, an additional wash with 500 µL of 50% methanol as a strong wash step was
adopted before the final elution with 100% methanol. Varying elution volumes of 25, 50, 75, 100,
150 and 200 µL were evaluated as well to obtain high recoveries and less interference. The maximum
recoveries were achieved for all analytes with the elution volume of 100 µL. To avoid the solvent
effect and achieve sharp peaks, the collected eluent needed to be diluted with 100 µL of water before
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instrumental analysis. Finally, the optimized extraction procedure was obtained as described in the
method section.
To determine the total amount of each analyte including the conjugated forms, enzymatic
hydrolysis is necessary. Since ZEN biomarkers in body fluids commonly occurred in the low ng mL−1
range, there was no need to worry about the adequacy of enzyme. On the other hand, the enzyme
amount might should be optimized to minimize the exogenous interferences that influence analyte
extraction and matrix effect. Spiked serum samples (10 ng mL−1 for each analyte) together with
varying levels of enzyme (100, 200, 500, 1000, 2000 and 5000 U mL−1) were incubated at 37 ◦C for
18 h. The recoveries of five analytes, except for β–ZAL, reduced in different degree while the enzyme
concentration up to 2000 U mL−1, as shown in Figure 2. Therefore, the concentration of 1000 U mL−1
was chosen in further study.
Figure 2. Optimization of enzyme concentration.
The sample preparation with the PRiME HLB µElution plate eliminated laborious steps of
evaporation and reconstitution. Under the optimized condition, this method drastically improved
the efficiency, allowing 96 samples to be processed in 1 h with good recoveries and well controlled
matrix interference.
3.4. Method Validation
The validation in terms of linearity, selectivity, accuracy (RM), precision (intra- and inter-day
variability), sensitivity (LOD and LOQ) and carry over was conducted according to the guidelines.
The linearity was tested by a calibration curve including eight levels of 0.2, 0.5, 1, 2, 5, 10, 20 and
50 ng mL−1. The calibration curve was built by plotting the peak area ratio of each analyte to IS versus
the concentration ratio of analyte to IS with a linear regression weighting factor of 1/concentration.
Regression coefficients (R2) of the calibration curves were greater than 0.9978 with deviations less than
12% for all concentrations, indicating a good linearity within the ranges defined.
The mothed should be able to differentiate the target analyte and endogenous components in
matrices. The selectivity was proved using 8 individual blank serum samples, which were analyzed
before and after fortified with target analytes at levels close to the LOQs. No obvious interferences from
endogenous components were observed at the retention time of each analyte, as shown in Figure 3.
In addition, the complete chromatographic separation of all the target compounds provided further
evidence for the high specificity of the method.
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Figure 3. The chromatograms of blank serum sample (a) and spiked sample at 0.1 ng mL-1 (b).
The Sensitivity (LOD/LOQ) of the assay were obtained by analyzing spiked serum samples at
low levels. The LOD and LOQ for each analyte were determined as signal to noise ratio (S/N) greater
than 3 and 10, which ranged 0.02–0.06 ng mL−1 and 0.1 and 0.2 ng mL−1 respectively for all target
compounds, as given in Table 2. The values demonstrated a high improvement in sensitivity [24,27–30].
Table 2. Extraction recovery, matrix effect, accuracy, precision and sensitivity of the method.
Analyte RE (Extractionrecovery, %)
Matrix
Effect
(%)
Precision % Spiked Value
(ng mL-1)
RM (Method
recovery, %) LOQ (ng mL
−1) LOD (ng mL−1)
Intra-day Inter-day
ZEN 94.06 85.2 2.53 3.62
0.5 119.5 0.1
(3 fmol)
0.02
(0.6 fmol)1 110.1
5 102.2
α-ZOL 99.95 78.09 3.12 4.29
0.5 100.4 0.2
(6 fmol)
0.04
(1 fmol)1 103.6
5 109.0
β-ZOL 111.8 84.17 3.81 4.96
0.5 91.6 0.2
(6 fmol)
0.06
(2 fmol)1 92.9
5 92.4
α-ZAL 106.5 76.83 4.32 8.22
0.5 105.6 0.2
(6 fmol)
0.04
(1 fmol)1 110.0
5 106.5
β-ZAL 116.1 77.24 4.25 5.98
0.5 100.5 0.1
(3 fmol)
0.02
(0.6 fmol)1 106.1
5 103.2
ZAN 100.4 81.77 5.99 7.04
0.5 123.6 0.1
(3 fmol)
0.03
(1 fmol)1 110.7
5 100.1
The accuracy and precision were investigated from six replicates of fortified serum samples at
three levels (0.5, 1.0 and 5.0 ng/ mL) once a day on three consecutive days. Method recovery (RM)
which had been corrected by IS were from 91.6% to 123.6% for all the analytes at three concentrations
(Table 2). The relative standard deviation (RSD) of intra-day and inter-day, representing the precision
of the method, were ranged 2.53%–5.99% and 3.62%–8.22%, respectively. Besides, extraction recovery
(RE) of sample preparation step and the matrix effect (signal suppression/enhancement, SSE) of
instrument analysis step showed great results, meaning that acceptable accuracy can also be achieved
even without IS compensation.
No carry-over was observed within the assay which was performed by injecting three blank
solvents after injection of a high concentration standard at 100 ng mL−1.
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3.5. Method Application to Real Samples
Using the proposed method, 125 serum samples collected from healthy volunteers in Henan
Province were measured. For each volunteer, the paired serum and urine samples were collected and
the 125 urine samples have already been tested and included in our recent study on ZEN internal
exposure assessment that was based on a total of 301 urine samples [33].
For the paired urine samples, ZEN, α-ZOL, β-ZOL and ZAN were detected. ZEN showed
the highest detection rate of 75.2%, followed by β-ZOL (21.6%), α-ZOL (5.6%) and ZAN (1.6%).
Alpha-ZAL and β-ZAL were absent in all these urine samples. The mean concentration and range
of each analyte were as following: ZEN (mean 0.31 ng/mL, range ND~3.68 ng/mL), β-ZOL (mean
0.084 ng/mL, range ND~1.32 ng/mL), α-ZOL (mean 0.051 ng/mL, range ND~2.64 ng/mL) and ZAN
(mean 0.019 ng/mL, range ND~0.518 ng/mL). The results were comparable with those reported for
other countries, normally with the mean concentration between 0.009~1.82 ng/mL [22,23,26,32–37].
On the contrary, among the serum samples, only one was found to be positive for ZEN after
enzyme digestion, whose chromatogram was presented in Figure 4. ZAN, α-ZOL, β-ZOL, α-ZAL and
β-ZAL were all absent. It can be attributed to the rapid clearance and excretion of ZEN from blood
after oral intake.
Figure 4. Chromatograms of a positive sample (a) and a negative sample (b).
Up to now, very limited data are available in this area as collected in Table 3. ZEN and its
metabolites were hardly detected in human serum or plasma [32,38], except for some patients [39,40].
They were commonly detected in animal serum/plasma after oral administration of high amount
of ZEN [4,24,28,29]. Compared to theses previously reported works, the method developed here
possessed a higher sensitivity for ZEN and its derivatives in blood, which can be applicable for disease
research and toxicokinetic study. Additionally, the results of paired serum-urine samples in this study
suggested that for ZEN biomonitoring and internal exposure study for healthy people, urine would be
a preferred medium because of the higher concentration and longer lifetime.
Table 3. Occurrence of ZEN biomarkers in human serum/plasma.
Country N Positive LOD/LOQ(ng/mL)
Means/Medians
(Ranges, ng/mL) References
Germany 50 0 (ZAN,ZEN) 1.0/1.0 <LOD [38]
Italy 233 5.4% (ZEN) 1.0 0.1(<LOD~3.9) [39]
Italy 63 6 (ZEN,
α-ZOL)
0.025/0.05 (ZEN, α-ZOL)
0.25/0.5 (β-ZOL, α-ZOL,
β-ZOL)
0.106 (α-ZOL), 0.934 (ZEN) [40]
USA 30 1 — <LOQ [32]
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4. Conclusions
A sensitive and high-throughput LC-MS/MS method was developed and validated for the
analysis of ZEN and its five metabolites in serum samples using 96-well PRiME HLB µElution plate.
It provided a simple and concurrent multiple sample treatment strategy without evaporation and
reconstitution steps. The developed method significantly improved sensitivity and selectivity and
reduced the labor-intensity, time consumption and waste generated at the same time. Although high
sensitivity and good recoveries were achieved for all the analytes, ZEN and its derivatives were hardly
detected in serum samples from healthy subjects due to their fast clearance and excretion from blood.
The timing of sampling after oral intake may strongly affect the residue levels of ZEN biomarkers
in serum.
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